Quarterly Report 1 25/26

Diamyd Medical reported Q1 (Sep–Nov 2025) net sales of MSEK 0.2 and a net loss of MSEK -48.8 (result per share SEK -0.4), with cash and short-term investments of MSEK 233.2 at Nov 30, 2025. The company completed screening in its pivotal, genotype‑defined Phase 3 DIAGNODE-3 trial and secured FDA alignment that shortens primary efficacy follow‑up to 15 months, enabling an accelerated primary readout (interim ~170 patients) at end-March 2026 and potential US accelerated approval; additional positives include global non-proprietary name assignment (retogatein), new patents (Hong Kong, Eurasia) and expanded manufacturing partnerships. These clinical and regulatory milestones materially increase upside conditional on the March 2026 interim efficacy readout, while the quarter’s cash runway and operating loss drive near-term financing and execution risk.

Analysis

Market structure: A materially positive March-2026 interim for retogatein would concentrate gains on Diamyd Medical (DMYD B) and specialist CDMOs (APL, NorthX Biologics), likely re-rating DMYD by 2–5x near-term if C‑peptide preservation meets statistical significance (p<0.05) in ~170 subjects. Insulin-device/CGM incumbents (DXCM, MDT, PODD) are neutral-to-beneficiaries if improved endogenous insulin reduces long‑term device spend, but near-term pricing power remains unchanged. Manufacturing supply tightness for biologics favors regional CDMOs; demand shock for rhGAD65 would be small relative to global biologics capacity but strategic for Swedish biotech cluster.

Risk assessment: Key tails include FDA reversing accelerated approval guidance, emergence of safety signals on broader population, or a failed C‑peptide effect at interim — each could cut equity value >70%. Financial runway is explicit: cash SEK 233.2m vs. quarterly burn ~SEK 43–44m implies ~5–6 quarters of runway (into mid‑2027) before likely dilutive financing, so funding risk is medium-high. Hidden dependencies: successful commercialization hinges on scalable GMP supply from Umeå and timely inspections; any manufacturing delay nullifies approval momentum.

Trade implications: Tactical long in DMYD B into March 2026 is a binary but asymmetric trade; hedge sector and event risk with a modest short in XBI/IBB or protective puts. Use calibrated option structures (buy-call spreads if available, long puts or collars for downside protection) around the interim; set clear liquidity and slippage limits given low cap liquidity. Rotate modest gains into higher‑conviction mid/small‑cap immunotherapy names and CDMO exposure post‑data.

Contrarian angles: Consensus overweights regulatory friendliness; remember antigen‑specific therapies historically struggle in broad populations — the genotype restriction (HLA DR3‑DQ2 ~40% of T1D) is both a strength and a commercial limiter. Positive interim driven by surrogate (C‑peptide) can be reversed at full readout or in real‑world outcomes; price in a 30–45% chance of true approval/pivotal success at interim and maintain tight stop‑losses.

Key Decisions for Investors

• Establish a 2–3% long position in Diamyd Medical (DMYD B) now to capture upside into the March 2026 interim readout; use a 30% stop-loss and plan to trim to 1% if share gains exceed 150% post‑interim or if p<0.05 C‑peptide preservation is announced.
• Hedge sector/event risk by shorting 0.5% notional of SPDR S&P Biotech ETF (XBI) or iShares Nasdaq Biotechnology (IBB) as a pair trade (long DMYD 2%, short XBI 0.5%) to neutralize broad biotech beta through March–June 2026.
• If liquid options exist, buy a modest call spread on DMYD with expiry April–June 2026 (cap upside, limit premium) OR, if no DMYD options, buy 3‑month 10–15% OTM puts on XBI (size 0.5% portfolio) to protect against a biotech sector selloff triggered by a negative DIAGNODE‑3 readout.
• Monitor cash runway and dilutive risk: reduce DMYD exposure to <0.5% immediately if cash falls below SEK 150m or company announces a financing or manufacturing delay; conversely increase to 3–4% within 2 weeks if interim shows ≥20% absolute C‑peptide preservation vs placebo with p<0.05 and FDA signals support for accelerated approval.